C-WC8RVasa Therapeutics
MMP inhibition, apelin analogs, cardiovascular aging
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WC8R
C-WC8RC-WC8RMMP inhibition, apelin analogs, cardiovascular aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Vasa Therapeutics MMP inhibition, apelin analogs, cardiovascular aging
Vasa Therapeutics is a biopharmaceutical company discovering and developing therapeutics that target the pathophysiology of cardiovascular aging. Its pipeline includes VS-041, a narrow-spectrum MMP-2 and MMP-9 inhibitor for HFpEF, and long-acting apelin programs for PAD, neuromuscular diseases, and sarcopenia. The company has locations in California and Poland.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Vasa Therapeutics — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic